ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

OPTI Optibiotix Health Plc

17.50
0.25 (1.45%)
Last Updated: 08:06:20
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 1.45% 17.50 17.00 18.00 17.50 17.25 17.25 120,641 08:06:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 6.16 15.96M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 17.25p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £15.96 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 6.16.

Optibiotix Health Share Discussion Threads

Showing 47776 to 47799 of 147675 messages
Chat Pages: Latest  1923  1922  1921  1920  1919  1918  1917  1916  1915  1914  1913  1912  Older
DateSubjectAuthorDiscuss
07/1/2019
18:28
Updated (growing) list:Current and future revenue streams confirmed so far:- GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance)- Sacco/CSL- HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical)- Pharmabiota- Galenicum Special Ingredients - Knighton Foods- Cereal Ingredients Inc.- Fine Foods & Pharmaceuticals- Trigen Pharma- Cambridge Commodities - Akums Drugs and Pharma- Seed Health- John Morley's - Alfasigma- Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution.- Unnamed US pharma partner (cholesterol strain)- Bened Biomedical- Bulgarian CholBiome distributor (thought to be Velinoff Pharma)- CTC Group- Formulation Creations- US Pharma Lab Inc.- Unnamed Greece and Cyprus CholBiome distributor- Unnamed Greece and Cyprus SlimBiome Medical distributor - Zeon Lifesciences Revenue not confirmed yet:- Tata X 2 (Slimbiome and LPGOS)- Mystery US Slimbiome customer- Paradise Fruits (Slimbiome)- Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL)Products on the market (already or soon) but not RNSed:- MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic- SilvExpo - RSM CardioPro and CholBiome - Aragan - Biotic•P3
parob
07/1/2019
18:10
SOH has said potential deal in China, ProBiotix IPO this year and given a clear direction of travel for the next year or so. It is positive and perhaps doubters should listen to that interview once more.
rafboy
07/1/2019
17:36
Judi, if I had a pound for every time I've heard the word transformational, I would be as wealthy as some of the peeps on this board!
dazah
07/1/2019
17:24
Good interview from Mr OH
All lining up nicely for the genuine and patient long termers
Transformational couple of years from now on in
imho

judijudi
07/1/2019
17:08
Not as strong finish as I'd have liked.

Overall feeling..."meh"

dazah
07/1/2019
16:53
hTTps://mobile.twitter.com/19AJS75/status/1082315874852327425
parob
07/1/2019
16:10
Look at SBTX today!
dazah
07/1/2019
16:03
https://www.proactiveinvestors.co.uk/companies/stocktube/11711/optibiotixs-slimbiome-gathers-steam-as-subsidiary-eyes-potential-ipo-11711.htmlSOH interview out today
riskybusiness1
07/1/2019
16:02
New SOH Interview just outOptiBiotix's SlimBiome gathers steam as subsidiary eyes potential IPO15:52 07 Jan 2019Life sciences firm OptiBiotix Health plc (LON:OPTI) has clinched a number of deals for its SlimBiome weight loss product as the company eyes up a potential initial public offering (IPO). Founder and CEO Stephen O'Hara tells Proactive London how OptiBiotix is changing from an R&D company to a business with greater commercial focus with a number of new deals in 2019 and our prodcuts migrating into other territories.The group has just inked an agreement with Indian firm Zeon Lifesciences Ltd, granting it an exclusive licence to manufacture and supply SlimBiome in the return in return for a 50% share of the profits.hTTps://tinyurl.com/yano3ttb
parob
07/1/2019
15:24
sbtx starting to move now up 10%
manc10
07/1/2019
14:34
velinoff Pharma

A Natural Way for Better Heart Health!

Posted on 07.01.2019 by velinoff

Cardiovascular diseases (GCC) are the leading cause of death worldwide, with cholesterol being a major factor.
Cholesterol is needed to build up cells and hormones, but excessive amounts are associated with an increased risk of GCC. Of the two major forms of cholesterol, LDL (Low Density Lipoprotein) is responsible for obstruction of the arteries, which can lead to GCC, while HDL (high density lipoprotein) helps to clear cholesterol from the blood. Therefore, it is important not only to maintain healthy levels of total cholesterol but also a good ratio of HDL to LDL.
Restricting cholesterol intake is important. However, since the liver naturally produces significant amounts of cholesterol, and complete elimination from food is impossible, additional measures are recommended. CholBiome ® X3 is the perfect solution.

The Natural Way for Better Heart Health!
CholBiome ® X3 is a last generation product of the Live Biotherapeutic Products group (LBP) combining three natural ingredients that help maintain healthy cholesterol levels. CholBiome ® X3 is supported by clinical trials and guarantees cardiovascular risk prevention.
CholBiome ® X3 strengthens the Cardiovascular System, naturally reducing cholesterol levels, lowering blood pressure, and reducing Cardiovascular Risk.

Mechanism of action:
CholBiome ® X3 works by changing the existing microbial - the natural intestinal flora of the individual to offer a natural, scientifically-based solution without side effects.
CholBiome ® X3 is an LBP therapeutics combining proven ingredients Monoclin K from red rice, Vitamin B3 (niacin) and patented Lactobacillus plantarum LPLDL ® :

- Lactobacillus plantarum LPLDL ® is a patented strain of OPTIBIOTIX HEALT Plc - a naturally occurring bacterium that acts by interrupting cholesterol recirculation in the body by ejecting unnecessary amounts of harmful cholesterol. In this way, the liver withdraws its blood cholesterol synthesis needed for the synthesis of bile salts, reducing its amount in the cardiovascular system. Lactobacillus plantarum LPLDL ® has an excellent ability to modulate the metabolism of bile acids. It has a positive benefit for heart health and factors such as high blood pressure and high cholesterol, as well as other processes from liver function to glucose regulation and vitamin metabolism.
- Monocoline K of red rice - inhibits cholesterol synthesis in the liver and maintains normal levels of cholesterol in the blood. It is a natural product obtained by the fermentation of yeast rice Monascus purpureus, a traditionally used medium for high cholesterol.
- Vitamin B3 (niacin) - modulates the degradation of fat in the cell, helping to maintain normal metabolism.

Clinical studies demonstrating the efficacy and safety of LPLDL ® :

Reduces total cholesterol by up to 36.7%
Reduces LDL cholesterol by up to 13.9%
Increases HDL cholesterol by up to 4.5%
Reduces systolic blood pressure by 5.1%
Fully safe *, well tolerated and without known side effects!
* compared to statins

Composition:
Patented bacterial strain Lactobacillus plantarum LPLDL ® - 4.10 9 CFU
Monocoline K - 10 mg
Vitamin B3 - 16 mg

Dosage:
Adults per 1 capsule daily in the morning on an empty stomach
Expected results: after the first month
Course of therapy: minimum 3 months

scotty1
07/1/2019
14:19
Ceo indicates revenues are up 5-6x in the H2 2018 compared to H1. Business achieved break even on a month to month before YE as was stated along with an expectation to push the company into overall profitability this year.Another words these agreements are becoming fruitful and will keep on growing along with new partners, territories, products, applications and profits
riskybusiness1
07/1/2019
14:14
Buywell3. You could always invest your money in UKOG.
jamesrs1
07/1/2019
14:12
BW, if you read the lemming blog there are 'revenue bearing' deals, or turnover if that is what you want to call it. Look at the red text.
slartybartfaster
07/1/2019
14:06
Lots of signed agreements ... but no turnover ... no sales
buywell3
07/1/2019
14:01
From 8p to 96p in a little over four years. That’s a 12x increase. With everything that’s happening now and so many things to come in the near future,can it go 3x from here in the next three years. Company director locked in until double the price from 80p. Obesity being a worldwide problem. I can’t see anything better out there for myself to be invested in. Massive respect for research and information posted by The true Believers that always reconfirm my reason for being invested here.
jamesrs1
07/1/2019
13:59
'We believe partnering with Zeon is an important step in optimising the supply chain to facilitate the needs of EXISTING and new corporate partners in India and Southern Asia and anticipate FURTHER announcements in due course.'SOH executing the model & strategy phenomenally. The scalability & profitability potential really is mind blowing. Usually FCAP are useless but that piece posted by Sum is very interesting as it highlights manufacturers in the key markets (though doesn't mention Sacco); Europe, US & Asia. I find it incredible how they are able to negotiate profit share agreements in each. Not only signing tons of agreements but sequentially aligning them in each territory in order to set up a complete supply chain where Optibiotix license its technology to each level of the chain. All goes straight to the bottom line whilst costs remain tightly controlled.
riskybusiness1
07/1/2019
13:52
dazah - Thank you for your apology. If you can see your way to editing your original post, more befitting to what you truly intended to portray, I can remove my rantings and allow us to clear the air and allowing me to apologize to you for the misunderstanding.

TIA

Or was this a cunning ruse to draw me out from under my bushel? ;-)

elrico
07/1/2019
12:59
Well elrico we do appreciate your writings and apologies if there was a misunderstanding.
dazah
07/1/2019
12:57
8p to 94p spiking to £1.33 over a 4 year period looks pretty stable and progressive to me?If you want stability you should stick clear of AIM and head for blue chip stocks, though even they've been more volatile than usual the past year.
riskybusiness1
07/1/2019
12:56
"Even elrico in one of his blogs gave a nod to TWs advice to top slice."

I only see one way of reading the above line, and that is to suggest I agreed with TW's advise to "top slice." I did not agree at the time but concede it was correct.

Why else use me and the blog!!

End of discussion as far as I am concerned.

elrico
07/1/2019
12:53
That's correct Charlie.
dazah
07/1/2019
12:52
What is this? I've always said that I'm positive on OPTI I even buy lots of their products. That is not withstanding frustrations I have as notwithstanding the very wealthy investors here aka the LTHs I'm sure in the share price decline from 133p to 60-odd pence we lost a lot of PIs making losses. And so as I have said SOH should do his best to keep a sensible share price ship whilst we all appreciate and believe in the long term vision for OPTI.
dazah
07/1/2019
12:49
I'm going to go out on a limb and suggest he was referencing elricos mentioning of TW's sell recommendation in a negative light when I said gave a nod to it. I doubt he was suggesting elrico endorsed the top slicing.
charlieej
Chat Pages: Latest  1923  1922  1921  1920  1919  1918  1917  1916  1915  1914  1913  1912  Older